By Reuters March 30, 20209:10 PM UTCUpdated ago March 30 (Reuters) - Akero Therapeutics Inc: * AKERO THERAPEUTICS TO ANNOUNCE RESULTS FOR WEEK 12 EFFICACY ENDPOINTS FROM NASH PHASE 2A BALANCED ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Akero Therapeutics has been a focus of several analyst firms. Canaccord Genuity maintained a Buy rating on the company's stock, noting the potential of the drug candidate, Efruxifermin.

Explore Akero Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for AKRO. The bear market induced by the Federal Reserve’s monetary tightening ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

Akero Therapeutics, Inc. (NASDAQ: AKRO) President and CEO Andrew Cheng recently sold shares in the company, yielding a total of $178,728. The transaction, which took place on June 11, involved the ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

In a recent SEC filing, Rolph Timothy, Chief Scientific Officer of Akero Therapeutics, Inc. (NASDAQ: AKRO), disclosed the sale of company shares valued at approximately $1.74 million. The transactions ...

* AKERO THERAPEUTICS INC QTRLY LOSS PER SHARE $0.42 * AKERO THERAPEUTICS - EXPECTS TO HAVE DRUG PRODUCT AVAILABLE IN Q4 2020 TO SUPPLY PHASE 2B PORTION OF PHASE 2B/3 CLINICAL TRIAL BEGINNING IN H1 ...

Akero Therapeutics’ (NASDAQ:AKRO) is a good candidate for a basket of MASH players. The company’s EFX has differentiated itself well in pre-cirrhotic MASH, and the 96-week data may change the ...

Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ: AKRO), recently executed a notable share sale, as per the latest SEC filing. The timing is particularly interesting as ...